Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 4, 1996

Primary Completion Date

November 1, 2014

Study Completion Date

December 10, 2014

Conditions
Lymphoma
Interventions
RADIATION

131Iodine-Anti-B1 Radioimmunotherapy

Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.

DRUG

BEAM

Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran

Trial Locations (1)

68198-7680

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER

NCT00574509 - Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter